TFRC and systemic lupus erythematosus: Ganguly, R. et al. explored a novel lymphatic-targeted cyclosporine nanoparticle, specifically a biodegradable, CD71-targeting nanoparticle (P2Ns-GA), designed to enhance SLE therapy by targeting transferrin receptor 1 (CD71).